Fluidigm Underwriters Exercise Over-allotment Option | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluidigm today said that the underwriters for its initial public offering have exercised their over-allotment option, purchasing an additional 833,750 shares of the firm's common stock for $13.50 per share.

Fluidigm went public last week, selling 5,558,333 shares of common stock at a price of $13.50 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.